Cargando…

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2

The goal of this study was to explore the plasma proteome of myelodysplastic syndrome (MDS) patients with refractory anemia with excess blasts subtype 2 (RAEB-2) in comparison to healthy controls. 20 plasma samples were separated with 2D electrophoresis and statistically processed with Progenesis Sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majek, Pavel, Riedelova-Reicheltova, Zuzana, Suttnar, Jiri, Pecankova, Klara, Cermak, Jaroslav, Dyr, Jan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055597/ https://www.ncbi.nlm.nih.gov/pubmed/24958999 http://dx.doi.org/10.1155/2014/178709

Ejemplares similares

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia
por: Májek, Pavel, et al.
Publicado: (2011)

Improved Coomassie Blue Dye-Based Fast Staining Protocol for Proteins Separated by SDS-PAGE
por: Májek, Pavel, et al.
Publicado: (2013)

Peripheral Blood Mononuclear Cell Proteome Changes in Patients with Myelodysplastic Syndrome
por: Pecankova, Klara, et al.
Publicado: (2015)

Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1
por: Májek, Pavel, et al.
Publicado: (2011)

Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups
por: Majek, Pavel, et al.
Publicado: (2015)

Posttranslational Modifications of Red Blood Cell Ghost Proteins as “Signatures” for Distinguishing between Low- and High-Risk Myelodysplastic Syndrome Patients
por: Pecankova, Klara, et al.
Publicado: (2017)

Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin
por: Májek, Pavel, et al.
Publicado: (2010)

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity
por: Pecankova, Klara, et al.
Publicado: (2022)

Proteome changes of plasma-derived extracellular vesicles in patients with myelodysplastic syndrome
por: Pecankova, Klara, et al.
Publicado: (2022)

Extension of the Human Fibrinogen Database with Detailed Clinical Information—The αC-Connector Segment
por: Sovova, Zofie, et al.
Publicado: (2021)

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
por: Štikarová, Jana, et al.
Publicado: (2013)

A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis
por: Chrastinová, Leona, et al.
Publicado: (2019)

Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron Overload
por: Pimková, Kristýna, et al.
Publicado: (2014)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome
por: Lee, Suee, et al.
Publicado: (2012)

Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II)
por: Wollina, Uwe, et al.
Publicado: (2017)

Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome—Refractory anemia with excess blasts type 2
por: Zanella, Anaïs, et al.
Publicado: (2019)

Impact of posttranslational modifications on atomistic structure of fibrinogen
por: Sovová, Žofie, et al.
Publicado: (2020)

Endothelialization of an ePTFE vessel prosthesis modified with an antithrombogenic fibrin/heparin coating enriched with bound growth factors
por: Táborská, Johanka, et al.
Publicado: (2021)

Molecular Dynamic Simulations Suggest That Metabolite-Induced Post-Translational Modifications Alter the Behavior of the Fibrinogen Coiled-Coil Domain
por: Sovova, Zofie, et al.
Publicado: (2021)

Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts
por: Costello, Régis T., et al.
Publicado: (2015)

Pseudomonas aeruginosa ventriculitis following pancytopenia due to myelodysplastic syndrome with an excess of blasts type 2
por: Scorza, Carla Alexandra, et al.
Publicado: (2023)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021)

Additional information offered by single nucleotide polymorphism array advantages in two myelodysplastic syndromes with excess blasts cases and future perspectives
por: Noronha, Thiago Rodrigo de, et al.
Publicado: (2019)

The Effect of Reagents Mimicking Oxidative Stress on Fibrinogen Function
por: Štikarová, Jana, et al.
Publicado: (2013)

Tryptophan Metabolism, Inflammation, and Oxidative Stress in Patients with Neurovascular Disease
por: Hajsl, Martin, et al.
Publicado: (2020)

Fibrin Clot Formation under Oxidative Stress Conditions
por: Kaufmanova, Jirina, et al.
Publicado: (2021)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2018)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia
por: Jekarl, Dong Wook, et al.
Publicado: (2010)

Implications of the 5(th) Edition of the World Health Organization Classification and International Consensus Classification of Myeloid Neoplasm in Myelodysplastic Syndrome With Excess Blasts and Acute Myeloid Leukemia
por: Lee, Cheonghwa, et al.
Publicado: (2023)

Linking aberrant glycosylation of plasma glycoproteins with progression of myelodysplastic syndromes: a study based on plasmonic biosensor and lectin array
por: Chrastinová, Leona, et al.
Publicado: (2023)

Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms
por: WU, HUANLING, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_57calq6ooadjueluii0n0mrtio